• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

去势敏感性转移性前列腺癌的治疗。

Treatment of Castration-naive Metastatic Prostate Cancer.

机构信息

Institut Gustave Roussy, Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France; Centre Hospitalier de l'Université de Montréal, Montréal, Canada.

Institut Gustave Roussy, Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France.

出版信息

Eur Urol Focus. 2017 Dec;3(6):518-521. doi: 10.1016/j.euf.2018.02.004. Epub 2018 Feb 27.

DOI:10.1016/j.euf.2018.02.004
PMID:29500136
Abstract

Both docetaxel+androgen deprivation therapy (ADT) and abiraterone acetate 1000mg/d+prednisone/prednisolone 5mg/d+ADT improved survival in patients with metastatic castration-naive prostate cancer. Their use should be offered and guided by patient's own characteristics.

摘要

多西他赛+雄激素剥夺疗法（ADT）和醋酸阿比特龙 1000mg/d+泼尼松/强的松 5mg/d+ADT 均改善了转移性去势敏感前列腺癌患者的生存。应根据患者自身特点提供并指导其使用。

相似文献

1
Treatment of Castration-naive Metastatic Prostate Cancer.去势敏感性转移性前列腺癌的治疗。
Eur Urol Focus. 2017 Dec;3(6):518-521. doi: 10.1016/j.euf.2018.02.004. Epub 2018 Feb 27.
2
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.新诊断转移性去势敏感性前列腺癌患者中阿比特龙联合泼尼松添加到雄激素剥夺治疗后的患者报告结局（LATITUDE）：一项国际性、随机 3 期临床试验。
Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.
3
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.既往内分泌治疗对醋酸阿比特龙治疗转移性去势抵抗性前列腺癌临床疗效的影响：3期随机研究的事后分析
Eur Urol. 2016 May;69(5):924-32. doi: 10.1016/j.eururo.2015.10.021. Epub 2015 Oct 24.
4
Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.醋酸阿比特龙与多西他赛联合雄激素剥夺疗法治疗高危和转移性激素初治前列腺癌的比较：系统评价和网络荟萃分析。
Eur Urol. 2018 Jun;73(6):834-844. doi: 10.1016/j.eururo.2017.10.002. Epub 2017 Oct 14.
5
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.醋酸阿比特龙联合泼尼松和多西他赛治疗转移性去势抵抗性前列腺癌的 1b 期研究。
Eur Urol. 2016 Nov;70(5):718-721. doi: 10.1016/j.eururo.2016.01.028. Epub 2016 Feb 3.
6
Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors.醋酸阿比特龙治疗化疗初治转移性去势抵抗性前列腺癌：一项疗效、安全性和预后因素的单中心前瞻性研究。
BMC Urol. 2018 Dec 3;18(1):110. doi: 10.1186/s12894-018-0416-6.
7
Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.首次雄激素剥夺治疗的反应持续时间、去势抵抗性前列腺癌的发生时间以及接受醋酸阿比特龙治疗的转移性去势抵抗性前列腺癌患者的结局。
Anticancer Drugs. 2017 Jan;28(1):110-115. doi: 10.1097/CAD.0000000000000434.
8
Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration.美国退伍军人事务部转移性去势敏感前列腺癌的治疗模式和生存情况。
Cancer Med. 2021 Dec;10(23):8570-8580. doi: 10.1002/cam4.4372. Epub 2021 Nov 2.
9
Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy.醋酸阿比特龙在接受雄激素剥夺治疗不同时长的韩国转移性去势抵抗性前列腺癌患者中的临床疗效
Korean J Urol. 2015 Aug;56(8):580-6. doi: 10.4111/kju.2015.56.8.580. Epub 2015 Aug 6.
10
The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.LACOG-0415 二期临床试验：醋酸阿比特龙联合 ADT 对比阿帕鲁胺对比醋酸阿比特龙联合阿帕鲁胺用于非去势睾酮水平的晚期前列腺癌患者。
BMC Cancer. 2019 May 23;19(1):487. doi: 10.1186/s12885-019-5709-y.

引用本文的文献

1
Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).转移性去势敏感性前列腺癌治疗共识：首届发展中国家全球前列腺癌共识会议（PCCCDC）报告
JCO Glob Oncol. 2021 Apr;7:550-558. doi: 10.1200/GO.20.00505.